Last reviewed · How we verify
NCT03779828: HELIPAD 1
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
trial testing HOME LINK in Chronic Inflammatory Demyelinating Polyneuropathy in 11 participants. Terminated before completion.
3 June 2019
Quick facts
| Lead sponsor | CSL Behring |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 11 |
| Start date | 27 November 2017 |
| Primary completion | 3 June 2019 |
| Estimated completion | 3 June 2019 |
| Sites | 10 locations across France |
Drugs / interventions tested
- HOME LINK
Conditions studied
- Chronic Inflammatory Demyelinating Polyneuropathy — all drugs for Chronic Inflammatory Demyelinating Polyneuropathy →
Sponsor
CSL Behring — full company profile →
Who can join
Eligibility, any sex, with Chronic Inflammatory Demyelinating Polyneuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course. Diagnosis is based on clinical presentation and electrophysiological findings in accordance with the EFNS/PNS consensus guidelines. IVIg is the first line treatment witch has been shown to be effective in several placebo-controlled trials. Once IVIg therapy produces a response and is well tolerated, some patients are able to continue their treatment in the home setting. The HOME LINK system offers an integrated, global solution based on telemonitoring technology providing continuous, remote monitoring of Privigen® infusions administered at home.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03779828
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Inflammatory Demyelinating Polyneuropathy
Currently open trials in the same condition.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07091630 — A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP · Phase 3 · recruiting
- NCT07154524 — Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · recruiting
- NCT07027111 — Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP · Phase 2 · active not recruiting
- NCT06858579 — A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy · Phase 3 · recruiting
Other CSL Behring trials
Trials by the same sponsor.
- NCT07326592 — Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza · Phase 4 · not yet recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
- NCT07332091 — Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary He · Phase 2 · recruiting
- NCT07094087 — Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovasc · Phase 3 · recruiting
- NCT07048262 — Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NC · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03779828 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CSL Behring
- Last refreshed: 15 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03779828.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing